Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma

被引：0
作者：
O'Byrne, Paul M. [1 ]
Bleecker, Eugene R. [2 ]
Bateman, Eric D. [3 ]
Busse, William W. [4 ]
Woodcock, Ashley [5 ]
Forth, Richard [6 ]
Toler, Tom [7 ]
Jacques, Loretta [8 ]
Lotvall, Jan [9 ]
机构：
[1] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[2] Wake Forest Univ Hlth Sci, Ctr Genom & Personalized Med, Winston Salem, NC USA
[3] Univ Cape Town, Dept Med, Rondebosch, South Africa
[4] Univ Wisconsin, Dept Med, Madison, WI USA
[5] Univ Manchester, Sch Translat Med, Manchester, Lancs, England
[6] GlaxoSmithKline, Quantitat Sci Div, Res Triangle Pk, NC USA
[7] GlaxoSmithKline, Resp Med Dev Ctr, Res Triangle Pk, NC USA
[8] GlaxoSmithKline, Resp Med Dev Ctr, Uxbridge, Middx, England
[9] Univ Gothenburg, Krefting Res Ctr, Gothenburg, Sweden
来源：
EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷
关键词：
Treatments; Asthma; -; management;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
3151
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
    Woodcock, Ashley
    Bateman, Eric D.
    Busse, William W.
    Lotvall, Jan
    Snowise, Neil G.
    Forth, Richard
    Jacques, Loretta
    Haumann, Brett
    Bleecker, Eugene R.
    RESPIRATORY RESEARCH, 2011, 12
  • [32] Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
    Ashley Woodcock
    Eric D Bateman
    William W Busse
    Jan Lötvall
    Neil G Snowise
    Richard Forth
    Loretta Jacques
    Brett Haumann
    Eugene R Bleecker
    Respiratory Research, 12
  • [33] Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma
    Magnussen, Helgo
    Hofman, Jerzy
    Staneta, Pawel
    Lawo, John-Philip
    Hellwig, Michael
    Engelstaetter, Renate
    JOURNAL OF ASTHMA, 2007, 44 (07) : 555 - 563
  • [34] Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations
    Dransfield, Mark T.
    Calverley, Peter M. A. C.
    Bourbeau, Jean
    Jones, Paul
    Hanania, Nick A.
    Mahler, Doug A.
    Vestbo, Jorgen
    Wachtel, Andrew
    Martinez, Fernando
    Barnhart, Frank
    Sanford, Lisa
    Lettis, Sally
    Crim, Courtney C.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [35] A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome
    Ishiura, Yoshihisa
    Fujimura, Masaki
    Shiba, Yasutaka
    Ohkura, Noriyuki
    Hara, Johsuke
    Kasahara, Kazuo
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 35 : 28 - 33
  • [36] Comparative Meta-Analysis of the Efficacy of Once-Daily Fluticasone Furoate 100 μG Versus Twice-Daily Fluticasone Propionate 250 μG in Adolescents and Adults with Persistent Asthma
    Tomlinson, Ryan
    Parks, Daniel
    Martin, Alan
    LUNG, 2017, 195 (05) : 571 - 574
  • [37] Comparative Meta-Analysis of the Efficacy of Once-Daily Fluticasone Furoate 100 µG Versus Twice-Daily Fluticasone Propionate 250 µG in Adolescents and Adults with Persistent Asthma
    Ryan Tomlinson
    Daniel Parks
    Alan Martin
    Lung, 2017, 195 : 571 - 574
  • [38] Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects
    Allen, A.
    Henderson, A.
    Gupta, A.
    Renaux, J.
    Brealey, N.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [39] Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study
    Ashley Woodcock
    Jan Lötvall
    William W Busse
    Eric D Bateman
    Sally Stone
    Anna Ellsworth
    Loretta Jacques
    BMC Pulmonary Medicine, 14
  • [40] Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations
    Singh, D.
    Worsley, S.
    Zhu, C-Q
    Hardaker, L.
    Church, A.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
12345